Life Sciences: What's Next?
Working with Savills, we’ve looked at the companies merging new technologies with research developments in UK life sciences.
- The prevalence of academic spinouts in the UK’s life sciences industry
- How much equity investment and grant funding is being secured by high-growth life sciences companies
- The important sub-sectors of life sciences, with deep dives into AI drug discovery, vaccines, healthtech, microbiome-based therapies, immunotherapy, and cell and gene therapy
Here’s a sneak peek inside
About the authors
henry whorwood>
Henry leads Beauhurst’s Research & Consultancy, and is an expert on equity finance and high-growth business. He has worked on briefs for clients including Barclays, SyndicateRoom, Innovate UK, Smith & Williamson and the British Business Bank. He regularly gives presentations on finance and market trends at events around the UK. Henry studied Classics at the University of Oxford.
Daniel robinson>
Daniel conducts data manipulation, visualisation and analysis as part of the Research & Consultancy team. He has a background in business analysis and commercial copywriting in Australia and the United Kingdom. Daniel has previously worked at The Sunday Times Fast Track, Oxford University Press, and advertising network MullenLowe Group.
Freya Hyde>
Freya performs data analysis and visualisation in the Research & Consultancy team, with a focus on design, and has worked on projects for Barclays, EY and JP Morgan. She holds a BA in History (International) from the University of Leeds, which included a year at Fudan University in Shanghai.
More leads, more clients, less churn.
Get access to unrivalled data on all the companies you need to know about, so you can approach the right leads and at the right time.
Book a 40 minute demo today to see all the key features of the Beauhurst platform, as well as the depth and breadth of data available.
An associate will work with you to build a sophisticated search, returning a dynamic list of organisations matching your ideal client profile.